Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Myriad Genetics, Inc. - Common Stock (NQ: MYGN )

14.56 -0.09 (-0.61%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,214,857
Open 14.83
Bid (Size) 13.15 (10)
Ask (Size) 16.00 (3)
Prev. Close 14.65
Today's Range 14.44 - 14.98
52wk Range 12.04 - 29.30
Shares Outstanding 90,900,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Expert Outlook: Myriad Genetics Through The Eyes Of 8 Analysts
Via Benzinga
Myriad Genetics and CancerCARE for Life Announce Agreement to Advance Access to MyRisk with RiskScore Hereditary Cancer Test
From Myriad Genetics, Inc.
Via GlobeNewswire

Performance

YTD
+7.85%
+7.85%
1 Month
+16.29%
+16.29%
3 Month
-4.34%
-4.34%
6 Month
-48.48%
-48.48%
1 Year
-37.38%
-37.38%

More News

Read More
Myriad Genetics Announces Two New Patents Granted for its Molecular Residual Disease (MRD) Assay
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Unveils Groundbreaking Eight Weeks’ Gestation NIPT Study Results at Society for Maternal-Fetal Medicine Conference
From Myriad Genetics, Inc.
Via GlobeNewswire
Demystifying Myriad Genetics: Insights From 6 Analyst Reviews
Via Benzinga
Myriad Genetics and Lumea Collaborate to Enhance Access to the Prolaris Biomarker and MyRisk Hereditary Cancer Tests through BxLink Integration
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
Via Benzinga
Where Myriad Genetics Stands With Analysts
Via Benzinga
Myriad Genetics Introduces Online Prenatal Genetic Testing Resource
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Announces Hereditary Cancer Risk Assessment Program Study Published in Obstetrics & Gynecology
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2024 Financial Results and Introduces Full Year 2025 Financial Guidance
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Signs Agreement with Nationally Renowned Sports Broadcaster Hannah Storm to Promote the Importance of Knowing Family Cancer History
From Myriad Genetics, Inc.
Via GlobeNewswire
UPDATE – Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference
From Myriad Genetics, Inc.
Via GlobeNewswire
MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad’s molecular residual disease assay
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Issues Quality, Innovation, and Corporate Responsibility Report
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Provides Update on Discussions with UnitedHealthcare regarding Medical Policy for Pharmacogenetic Testing
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics’ RiskScore Study Named One of the Top 10 Significant Advances in Genomic Medicine in American Journal of Human Genetics
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Expands Board of Directors with Election of Mark S. Davis as New Board Member
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics’ Portfolio Elevated by Updated NCCN Prostate Cancer Guidelines
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium
From Myriad Genetics, Inc.
Via GlobeNewswire
This AMD Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
Via Benzinga
NCCN Prostate Cancer Guidelines Reinforce Status of Myriad Genetics' Prolaris® Test as an 'Advanced Tool' Recommended for Prognostic Assessment
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Announces Incorporation of its Proprietary HRD platform in Illumina’s Updated Comprehensive Gene Panel Assay, TruSight™ Oncology 500 v2
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Announces Prequel® Prenatal Screening Can Now be Performed Eight Weeks into Pregnancy
From Myriad Genetics, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.